GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

natalizumab   Click here for help

GtoPdb Ligand ID: 6591

Synonyms: AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Approved drug Immunopharmacology Ligand
natalizumab is an approved drug (FDA (2004), EMA (2006))
Compound class: Antibody
Comment: Natalizumab was the first migration-inhibitory biological drug to be approved for inflammatory diseases. It targets α4β1 integrin (VLA-4) on leukocytes to block interaction with vascular cell adhesion molecule 1 (VCAM-1) on inflamed endothelium, thus inhibiting leukocyte extravasation into sites of inflammation. It is active in peripheral tissues and the central vervous system.
Targeting cell migration-related molecules in immune conditions (and cancer) is regarded as a valid approach for the development of novel anti-inflammatory therapeutics [3]. The design and synthesis of this antibody was originally described in a 1997 publication [2].

Biosimilars:
The first natalizumab biosimilar was approved by the FDA in August 2023 and by the EMA a month later. Like the originator/reference agent, Tyruko® (natalizumab-sztn; Sandoz Inc.) is indicated for relapsing forms of multiple sclerosis and moderate-severe active Crohn's disease (when conventional therapies, including TNF-α inhibitors, are inadequate or not tolerated).
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: natalizumab

Classification Click here for help
Compound class Antibody
Approved drug? Yes. US FDA (2004)  |  EU EMA (2006)
International Nonproprietary Names Click here for help
INN number INN
7716 natalizumab
Synonyms Click here for help
AN100226 | anti-alpha4 integrin | anti-VLA4 | Tysabri®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 75
Reactome Drug Reactome logo R-ALL-9679737
Reactome Reaction Reactome logo R-HSA-9679740
Other databases
GtoPdb PubChem SID 178103204
PubChem SID 178103204
Search PubMed clinical trials natalizumab
Search PubMed titles natalizumab
Search PubMed titles/abstracts natalizumab
Wikipedia Natalizumab